SLU-PP-332 for Weight Loss: What the Evidence Shows
What human and animal studies show about SLU-PP-332 for weight loss, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- None found
- with an outcome for weight loss, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 1
- with an outcome for weight loss, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 1
- with an outcome for weight loss
Evidence for weight loss
Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Energy expenditure and fatty acid oxidation | In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Fat mass and insulin sensitivity | The ERR agonist reduced obesity and improved insulin sensitivity in mouse models of metabolic syndrome. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
SLU-PP-332 and weight loss are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Mouse results
SLU-PP-332 is described by its developers as an agonist of the estrogen-related receptors ERR alpha, beta and gamma that activates an acute aerobic exercise programme.[1]
In diet-induced obese and ob/ob mice, administration increased energy expenditure and fatty acid oxidation and decreased fat mass accumulation.[1]
The authors report reduced obesity and improved insulin sensitivity in mouse models of metabolic syndrome, and write that activating ERR may be an effective way to treat obesity.[1]
What is missing, and the sport rule
A pilot study treated myoblasts cultured from the muscle of inactive women with SLU-PP-332 in the dish; it did not dose people.[2]
WADA's current list names no ERR agonists in S4.4; its examples are insulin mimetics, meldonium and trimetazidine, so the compound's status is unclear rather than confirmed.[3]
Other peptides people research for weight loss
All peptides for weight loss, comparedCommon questions
Does SLU-PP-332 help with weight loss?
The strongest study we summarise for weight loss is animal evidence, across 1 study with an outcome for weight loss. That is not proof it works in people.
Is SLU-PP-332 approved for weight loss?
No. SLU-PP-332 is not FDA approved for any use, including weight loss.
What is the best peptide for weight loss?
There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.
Does SLU-PP-332 burn fat?
In obese mice it increased energy expenditure and fat oxidation and reduced fat mass accumulation; no human result exists.[1]
Is SLU-PP-332 an exercise mimetic?
That is the label its developers use, based on mouse experiments in which it activated an acute aerobic exercise programme.[1]
Is SLU-PP-332 allowed in sport?
It is not named on WADA's current list, but the list also has a catch-all class for substances with no approval, so the list text alone does not settle its status.[3]
More on SLU-PP-332
Sources
- 1A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 2Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
Found an error? Report a correction.